SCHEMBL21095773

SCHEMBL21095773

CC(C)c1ccc(-c2nnc(C(F)(F)F)s2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.58
NPC1 O15118 4/20 0.58
KDM4E B2RXH2 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
HPGD P15428 1/20 0.58
MAPT P10636 1/20 0.43
PAX8 Q06710 1/20 0.43
NOD2 Q9HC29 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
FFAR2 O15552 1/20 0.41
PTPN5 P54829 2/20 0.41
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
NOTUM Q6P988 2/20 0.37
TP53 P04637 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.35
MGAM O43451 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22116946 0.81 ALDH1A1 (0.48) RAB9ANPC1KDM4ESMN1; SMN2HPGD
SCHEMBL23328879 0.75 RAB9A (0.66) RAB9ANPC1KDM4ESMN1; SMN2HPGD
SCHEMBL13160177 0.75 RAB9A (0.66) RAB9ANPC1KDM4ESMN1; SMN2HPGD
SCHEMBL21095772 0.74 RAB9A (0.64) RAB9ANPC1KDM4ESMN1; SMN2HPGD
SCHEMBL10022384 0.74 KDM4E (1.00) RAB9ANPC1KDM4ESMN1; SMN2HPGD
SCHEMBL22116988 0.72 CSNK2A2 (0.59) HDAC1HDAC6
SCHEMBL23328878 0.72 RAB9A (0.45) RAB9ANPC1KDM4ESMN1; SMN2HPGD
SCHEMBL22116832 0.71 MAPT (0.51) RAB9ANPC1KDM4ESMN1; SMN2MAPT
SCHEMBL14087362 0.70 PTPN5 (0.59) PTPN5
SCHEMBL1505214 0.69 NR1H4 (0.62) RAB9ANPC1KDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239892-A1 COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF ARKUDA THERAPEUTICS (US) 2023-12-14 WO disclosed
EP-3724188-B1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2023-06-07 EP disclosed
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2021-06-03 US disclosed
WO-2019118528-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN1 RAB9A 2951/4885NPC1 325/4885KDM4E 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.